Primary axillary hyperhidrosis (PAH) is a common and distressing condition of excessive sweating along the axillary area without associated systemic disorders. In addition to the aforementioned treatment options, various energy-delivering modalities have been applied to improve PAH.
fat layer, which theoretically destroy the secretory portion of eccrine glands. Moreover, accompanying coagulation necrosis or thermal alteration of the intradermal ducts, fat tissue, and surrounding nerve fibers and microvasculature contributes to reduce axillary sweating. 2 Despite these promising results, the establishment of optimal parameters for maximizing the area of bulk thermal injury with sufficient tissue coagulation and for minimizing excessive thermal injury along the epidermis and upper dermis remain a concern for individual energy-delivering devices.
In this prospective, split-axilla, pilot study, we aimed to compare the efficacy and safety of invasive, bipolar RF treatment using insulated microneedle electrodes for PAH utilizing different treatment settings. To do so, a tissue-mimicking (TM) phantom study was first 
| MATERIAL S AND ME THODS

| Invasive bipolar RF treatment on TM phantom
A bipolar RF device (ONIX; Shenb Co., Ltd., Seoul, Korea) was utilized in this study to emit 0.5-MHz, 1-MHz, or 2-MHz RF oscillations via 36 insulated, microneedle electrodes arranged in a distinctive 6 × 6
pattern. Additionally, a TM phantom was prepared to simulate RFinduced tissue responses generated by 0.5-MHz and 2-MHz RF oscillations. To do so, a transparent gelatin phantom was developed by mixing 12.5% (w/v) gelatin (Sigma-Aldrich, St. Louis, MO, USA) with distilled water, as described in a previous report with minor modification. 10 The mixture was poured into polycarbonate housing immediately after removing gas and solidified in a refrigerator at 4°C for 12 hours. Then, 0.5-MHz or 2-MHz bipolar RF treatment was delivered to TM phantom via insulated microneedles at a penetration depth of 3 mm, RF conduction times from 1 s to 7 s (increments of 1 s), and a power of 29.3W for 0.5-MHz treatment and 15.1 W for 2-MHz treatment. RF treatment at each setting was performed using single, disposable tips, and treatment sites were spaced at least 2 cm apart to avoid generating thermal effects on other treatment sites.
Immediately after delivering a single shot from the RF device to the TM phantom in each experimental setting, photographs were taken from top to lateral views using a digital single-lens reflex camera (Nikon D300; Nikon Corp., Tokyo, Japan) with a micro Nikkor AF-S VR lens (Nikon Corp.) at a focal length of 105 mm and a f/2.8G internal focusing extra-low dispersion. All experiments were performed in triplet. 
| Patients and treatment protocol
| Objective and subjective outcome assessment
For objective evaluation, the starch-iodine test was performed on both the left and right axillae for all participants, and digital photographs were taken using a digital single lens reflex camera (Sony a-7;
Sony Corp., Tokyo, Japan) at baseline and at 1 and 3 months after RF treatment. The results of starch-iodine tests were scored separately on each side of the axilla at 1 month and 3 months after RF treatment, compared to baseline, according to the global improvement scale as "worse than before" (score: −1), "not applicable or unchanged" (score: 0), "slightly improved (1%-25%)" (score: 1), "moderately improved (26%-50%)" (score: 2), "markedly improved (51%-75%)" (score: 3), or "near totally improved (>75%)" (score: 4). Additionally, the HDSS was subjectively assessed separately for each side, and participants were surveyed for any side effects, including intolerable pain, secondary bacterial, viral, fugal, or mycobacterial infection, redness and edema, bruising, oozing, bleeding, postinflammatory hypo-or hyperpigmentation, scaling or crusting, or scarring.
Immediate in vivo tissue reactions were evaluated using 2-dimensional ultrasound study, and delayed reactions were assessed by histologic study. Immediately after 0. 
| Statistical analysis
Values are presented as median (IQR) unless otherwise noted.
Wilcoxon signed-rank test and McNemar's test by nonparametric criteria were performed using sas software, version 9.2 (SAS Institute
Inc., Cay, NC, USA). Additionally, a normality test was performed using Kolmogorov-Smirnov test, and HDSS and global improvement scale scores were analyzed via linear mixed models with Bonferroni post hoc analysis. Differences with P value < .05 were considered statistically significant.
| RE SULTS
| Patterns of RF-induced thermal coagulation in a gelatin-based TM phantom
To compare the morphologic patterns of RF-induced TIZs, 0. 
| Immediate RF-induced tissue reactions in 2-dimensional ultrasound study
At baseline, 2-dimensional ultrasound images obtained from both axillae using a linear high-frequency hockey stick transducer at a Figures 3B and 4B ). LC/LP setting were 1.5 (IQR, 1-2) (P = .004) at 1 month and 1 (IQR, 1-2) (P = .002) at 3 months after invasive, bipolar RF treatment, compared to baseline (Figures 5-7) . Meanwhile, the median HDSS scores of the other side treated at the SC/HP setting were 2 (IQR, 2-2) (P = .004) at 1 month and 2 (IQR, 1.25-2) (P = .002) at 3 months after treatment. Nonetheless, no significant differences were discovered between median HDSS scores at 1 month and 3 months between LC/LP and SC/HP settings (P > .05, respectively). and secondary bacterial, viral, fungal, or mycobacterial infection, were reported.
| Delayed RF-induced tissue reactions in histologic study
At baseline, differences in the number and size of eccrine and apocrine sweat glands between both left and right axillae were unremarkable (data not shown). At 3 months after 0.5-MHz, invasive RF treatment, skin specimens exhibited marked decreases in the number and size thereof with the treatment settings of LC/LP and SC/ HP. Particularly, the LC/LP-treated axilla presented more remarkable decreases in the size of eccrine and apocrine sweat glands, compared to the SC/HP-treated axilla ( Figure 8C) . Meanwhile, the SC/HP-treated axilla exhibited more pronounced reductions in the number of sweat glands, compared to the LC/LP-treated axilla ( Figure 8D) . None of the skin specimens presented abnormally large, dense, eosinophilic collagen bundles, which are suggestive features of hypertrophic scarring or keloids, in the dermis and subcutaneous fat layer.
| D ISCUSS I ON
RF-induced targeted thermal destruction of eccrine sweat glands can be achieved using invasive, disposable catheters or fraction- of thermal tissue injury are associated with the signal amplitude. 11, 12 Therefore, theoretically, the use of RF with a longer conduction time, higher signal amplitude, and more passes at different penetration depths of electrodes could be more effective in decreasing the sizes and numbers of eccrine and/or apocrine sweat glands. 5 As reported in previous studies, 5, 8 RF treatment in our study was delivered into the skin layers between the lower dermis and upper subcutaneous fat, targeting both the secretory and lower ductal portions of the eccrine sweat glands. In our study, mean global improvement scores increased significantly over the duration of 1 month after the RF treatment and decreased gradually thereafter. Nonetheless, no significant differences in mean global improvement scores were noted between 1 month and 3 months after RF treatment in both the LC/LP and SC/HP treatment settings. Accordingly, full-thickness skin specimens, who were obtained at 3 months after treatment, demonstrated remarkable decreases in, but not the complete disappearance of, eccrine sweat glands, without excessive collagen fiber formation. Additionally, the number and size of apocrine sweat glands also decreased, compared to the baseline, although they were still found in the subcutaneous fat layer.
Additionally, apocrine bromhidrosis of the axillae also noticeably improved after RF treatment in this study. We suggest that both decreased eccrine secretion and RF-induced thermal coagulation of apocrine sweat glands could have contributed to the clinical improvement of apocrine bromhidrosis. However, because the secretory parts of the apocrine sweat glands are located deeper in the subcutaneous fat layer than those of eccrine sweat glands, optimized treatment settings for apocrine bromhidrosis should be evaluated in the future via well-controlled studies with a large sample size.
In conclusion, our study demonstrated that 0.5-MHz, invasive, bipolar RF generates larger and more distinct TIZs than similar RF treatment at a frequency of 2 MHz. Additionally, via human splitaxilla study, we noted that the invasive, multilayered, multiplepass, 0.5-MHz, bipolar RF treatments significantly improved PAH without major side effects. In particular, we found RF delivery at the LC/LP treatment settings to be more effective and safer for treating PAH, compared to SC/HP. Notwithstanding, the clinical results of our split-axilla study are limited by the small sample size, preventing us from confirming the optimal treatment parameters for treating PAH using an invasive, bipolar RF device. Despite these limitations, we propose that invasive, multilayered, multiple-pass, 0.5-MHz, bipolar RF treatment provides an alternative or additional therapeutic modality for treating PAH, particularly at LC/LP treatment settings. 
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